We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+12.86%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$158M
AUM Growth
-$7.14M
(-4.3%)
Cap. Flow
-$21.7M
Cap. Flow
% of AUM
-13.81%
Top 10 Holdings %
Top 10 Hldgs %
5.64%
Holding
474
New
40
Increased
153
Reduced
231
Closed
49
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Expedia Group
EXPE
|
+$752K |
| 2 |
Gartner
IT
|
+$681K |
| 3 |
Trane Technologies
TT
|
+$681K |
| 4 |
Eaton
ETN
|
+$660K |
| 5 |
Prologis
PLD
|
+$658K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$854K |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$778K |
| 3 |
IDEX
IEX
|
+$731K |
| 4 |
Tesla
TSLA
|
+$719K |
| 5 |
Yum China
YUMC
|
+$714K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.36% |
| 2 | Technology | 15.51% |
| 3 | Financials | 14.54% |
| 4 | Industrials | 9.65% |
| 5 | Energy | 8.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCYC
326
Bicycle Therapeutics
BCYC
$270M
| $112K | 0.07% |
6,172
+2,467
| +67% | +$40.8K |
|
327
Kura Oncology
KURA
$792M
| $111K | 0.07% |
7,747
-877
| -10% | -$8.62K |
|
328
Apogee Therapeutics
APGE
$10.1B
| $111K | 0.07% |
+3,984
| New | +$79.9K |
|
329
Cullinan Oncology
CGEM
$1.06B
| $111K | 0.07% |
10,879
+2,475
| +29% | +$21.9K |
|
330
Cogent Biosciences
COGT
$6.77B
| $110K | 0.07% |
18,666
+10,966
| +142% | +$84K |
|
331
Allogene Therapeutics
ALLO
$625M
| $110K | 0.07% |
34,163
+14,328
| +72% | +$40.6K |
|
332
Keros Therapeutics
KROS
$197M
| $109K | 0.07% |
2,743
+182
| +7% | +$5.71K |
|
333
Neumora Therapeutics
NMRA
$308M
| $108K | 0.07% |
+6,328
| New | +$77.7K |
|
334
Nurix Therapeutics
NRIX
$2.45B
| $107K | 0.07% |
10,356
+1,345
| +15% | +$9.22K |
|
335
Arvinas
ARVN
$530M
| $107K | 0.07% |
2,595
-766
| -23% | -$17.9K |
|
336
Zymeworks
ZYME
$1.62B
| $107K | 0.07% |
10,264
-1,607
| -14% | -$12.8K |
|
337
Olema Pharmaceuticals
OLMA
$977M
| $105K | 0.07% |
+7,515
| New | +$101K |
|
338
Biohaven
BHVN
$2.03B
| $105K | 0.07% |
2,459
-1,598
| -39% | -$49.7K |
|
|
CMPS
339
Compass Pathways
CMPS
$1.47B
| $105K | 0.07% |
11,992
-557
| -4% | -$3.6K |
|
340
ALX Oncology
ALXO
$262M
| $105K | 0.07% |
7,019
-3,708
| -35% | -$35.2K |
|
|
RNAM
341
DELISTED
Avidity Biosciences
RNAM
| $104K | 0.07% |
11,529
+3,416
| +42% | +$22.8K |
|
342
Viridian Therapeutics
VRDN
$2.2B
| $104K | 0.07% |
4,787
+1,215
| +34% | +$19.2K |
|
343
Dyne Therapeutics
DYN
$4.15B
| $104K | 0.07% |
7,833
-139
| -2% | -$1.36K |
|
344
AnaptysBio
ANAB
$1.55B
| $104K | 0.07% |
4,862
-461
| -9% | -$7.95K |
|
345
Arcturus Therapeutics
ARCT
$164M
| $104K | 0.07% |
3,302
-280
| -8% | -$6.66K |
|
346
Xenon Pharmaceuticals
XENE
$6.1B
| $103K | 0.07% |
2,245
-79
| -3% | -$2.79K |
|
347
Relay Therapeutics
RLAY
$4B
| $102K | 0.07% |
9,295
+1,023
| +12% | +$8.63K |
|
348
Cabaletta Bio
CABA
$427M
| $102K | 0.06% |
+4,507
| New | +$75.8K |
|
349
Protagonist Therapeutics
PTGX
$8.54B
| $102K | 0.06% |
4,457
+1,017
| +30% | +$17.8K |
|
350
Celldex Therapeutics
CLDX
$2.95B
| $102K | 0.06% |
2,561
-70
| -3% | -$2.06K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q4 2023 Portfolio in Review
As of Q4 2023, Virtus ETF Advisers held 474 positions worth $158M, down 4.3% from $165M the previous quarter. Its ten largest holdings account for 5.6% of the portfolio.
Virtus ETF Advisers withdrew a net $21.7M in Q4 2023, closing 49 positions and reducing 231 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $854K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Financials.
Against the trend, Virtus ETF Advisers opened a new position in Expedia Group worth $932K.
- Virtus ETF Advisers's largest Q4 2023 buy was Expedia Group: 6,139 shares worth $932K.
- Virtus ETF Advisers added most to Pioneer Natural Resource Co. in Q4 2023, an estimated $535K increase.
- Virtus ETF Advisers's biggest Q4 2023 reduction was VICI Properties, cutting an estimated $659K.
- Virtus ETF Advisers fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $854K.
- Virtus ETF Advisers's ten largest holdings make up 5.6% of its $158M portfolio in Q4 2023.
- Virtus ETF Advisers opened 40 new positions and closed 49 in Q4 2023.
- Virtus ETF Advisers's portfolio value fell 4.3% quarter-over-quarter to $158M.
Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.